Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study — Sara Bringhen (2023) | RDL Network
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
Article 2023 en
Authors
SB
Sara Bringhen
LP
Luděk Pour
RB
Reuben Benjamin
Abstract
1 min read
Ixazomib is a feasible and effective maintenance option for prolonging PFS across this heterogeneous patient population.
Meletios A Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial
Meletios A Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial
Meletios A Dimopoulos, Jacob P. Laubach, Maria Asunción Echeveste Gutierrez, Norbert Grząśko, Craig C. Hofmeister, Jesús F. San Miguel, Shaji Kumar, Richard Labotka, Vickie Lu, Deborah Berg, Catriona Byrne, Zhaoyang Teng, Guohui Liu, Helgi van de Velde, Paul G. Richardson
Hartmut Goldschmidt, Meletios A Dimopoulos, S. Vincent Rajkumar, Katja Weisel, Philippe Moreau, Wee Joo Chng, Gábor Mikala, Michèle Cavo, Karthik Ramasamy, Kaveri Suryanarayan, Zhaoyang Teng, Richard Labotka, María‐Victoria Mateos
Discussion(0)
No comments yet. Be the first to comment.